it offers semaglutide and tirzepatide through its own Weight Management Protocols, and this review simply compares approaches across the GLP-1 telehealth space

may cause iron-deficiency anemia Nausea and vomiting particularly with stricturing disease/obstruction Urgency and tenesmus with rectal/colonic involvement Weight loss and malnutrition due to malabsorption, food avoidance, elevated metabolic demand Fever with active inflammation, abscess, or fistula Perianal disease fissures, fistulae, skin tags, abscesses Extraintestinal Manifestations Arthropathy peripheral or axial (enteropathic arthritis, M07.6x) Dermatologic: Erythema nodosum (L52), pyoderma gangrenosum, psoriasis (L40.5) Ocular: Uveitis/iritis (H20.01), episcleritis, scleritis Hepatobiliary: Primary sclerosing cholangitis (K73.2), fatty liver, cholelithiasis Metabolic: Osteopenia/osteoporosis (from steroid use and malabsorption), nephrolithiasis Hematologic: Anemia (iron deficiency, B12/folate deficiency, anemia of chronic disease) When a patient with Crohns disease is admitted with significant weight loss, malnutrition, or protein-calorie deficiency , query the provider to specify the degree of malnutrition (mild, moderate, severe protein-calorie malnutrition)

While its true that getting enough protein is critical to maintaining muscle mass while taking GLP-1s, many protein sources are high in fat
CS selectively binds to CD44 receptors, which are overexpressed in M1 macrophages, whereas the hydrophobic BR core ensures ROS sensitivity, facilitating intracellular ROS neutralization and oxidative stress attenuation
By activating GLP-1 receptors, these drugs enhance glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and influence central appetite signaling